As part of our ongoing aim to bring you reports of innovative developments, we have added a review of the recent ADAURA study which recorded overall survival with osimertinib in resected EGFR -mutated NSCLC.
Independent commentary is provided by Associate Professor Tom John, a medical oncologist at the Peter MacCallum Cancer Centre, Melbourne who specialises in thoracic malignancies.
Please login below to download this issue (PDF)